ABOUT US

關(guān)于我們

COMPANY PROFILE

Guangzhou Doublle Biological Products Co., Ltd. was founded by Dr. Wenlin Huang, who is virologist and oncologist. He is currently the rotating chairman of the Asia-Pacific Cell and Gene Therapy Association, an outstanding talent in Guangzhou Development Zone, a professor at Sun Yat-Sen University Cancer Center, and an honorary professor at the Chinese University of Hong Kong. Dr. Huang Wenlin has beenfocusing on the development and transformation of gene engineering technology to clinical applications such as tumor gene therapy, immune cell therapy, and vaccines.

Since its establishment, the company has always focused on technological research and development, and has formed a relatively complete development systemwith a tellented team led by Dr. Huang WenlinThroughout years of effort, the company has created a gene therapeutic development platform, and developed the cutting-edge core technologies which has enabled the company to continuously develop new biologics. As a supporting unit, two provincial-level enterprise key laboratories (engineering laboratories) for anti-tumor drug R&D and one municipal-level enterprise key laboratory for gene therapy have been established. Further more and five new drug R&D functional platforms have been established under the support of three laboratory platforms, including Gene therapy biologics commercial scale production and quality control platform, cell biotherapy R&D and manufacturing platform, tumor vaccine and specific immunotherapy product platform, construction of anti-tumor lead macromolecule candidates and pharmacodynamics platform, etc.

After decades of continuous innovation and development, our company has formed a sustainable product pipelines. including E10A, E10B, E10C, E10D, E10F, E10G, E10H, E10I, E10J, etc, just to name a few. Among them, E10A (Recombinant Human Endostatin Adenovirus Injection) is the first gene therapy drug to enter clinical phase III trials in China、E10H (Autologous Natural Killer Cell Injection) is the first NK cell therapy drug approved for clinical trials in China.

The company was established on May 28, 2001, and has long been committed to the development of innovative medicines for anti-tumor gene and targeted therapy.

National high-tech enterprise

Provincial Key Laboratory: Research and Development of New Drugs for Tumor with Targeted Therapy

Provincial Engineering Center: New Anti-Tumor Vaccine

Municipal Key Laboratory: Genetic biologicalR&D

The First Guangzhou's Top 100 Emerging Enterprises

Post-Doctoral Research Center

China's first gene therapy biologics E10A entered clinical phase III

China's first NK cell therapy drug E10H approved for clinical trials

COMPANY HIGHLIGHTS

More than 20 years of experience in large-scale development and application of adenovirus technology.

A research and development team dedicated to the development and transformation of innovative technologies for gene targeted therapy and cell therapy.

It is a cerified the national high-tech enterprise and the Guangdong Province secondary pathogenic microbiology laboratory.

The product E10A is the first in-class tumor treatment biologicas based on adenovirus vector technology that has entered clinical phase III in China.

Its product E10B, the first in-class tumor treatment biologicas for intratumoral injection of prostate cancer.

Doublle developed the first in-class autologous NK cell biologics accepted by CDE for clinical trials.

It has an ileading GMP manufacturing facility of nearly 10,000 square meters in compliance with the EU, FDA and China Food and Drug Administration, forming a sustainable development pipeline for a series of innovative anti-tumor biologics and vaccine products.